氨溴索雾化吸入治疗铜绿假单胞菌下呼吸道感染的临床研究

目的 评价氨溴索雾化吸入治疗铜绿假单胞菌(PAE)下呼吸道感染的临床效果及安全性.方法 将41例PAE下呼吸道感染的患者随机分为两组,对照组选择对PAE敏感的哌拉西林/他唑巴坦、左氧氟沙星联合治疗,试验组在对照组治疗的基础上加用氨溴索雾化吸入,疗程均为10～14 d.结果 试验组痊愈率为65.0％,有效率为85.0％；对照组痊愈率为33.3％,有效率为66.7％,两组痊愈率差异有统计学意义(P＜0.05),有效率差异无统计学意义；试验组及对照组细菌清除率分别为75.0％和42.9％,差异有统计学意义(P＜0.05).结论 氨溴索雾化吸入辅助治疗PAE下呼吸道感染,有助于清除PAE,有可能成为理想的治疗方案.

Clinical study of inhaled ambroxol in the adjunctive treatment of lower respiratory tract infection induced by Pseudomonas aeruginosa

OBJECTIVE To evaluate the efficacy and safety of inhaled ambroxol in the adjunctive treatment of the lower respiratory tract infection induced by Pseudomonas aeruginosa.METHODS A total of 41 patients with lower respiratory tract infection induced by P.aeruginosa were randomly divided into two groups.The control group received the combination therapy of piperacillin/tazobactam and levofloxacin,while the trial group received inhaled ambroxol plus the combination therapy.The course of treatment for both groups was 10-14 d.RESULTS The clinical cure rates of trial group and control group were 65.0%and 33.3%,respectively,and clinical efficacy rates were 85.0% and 66.7%,respectively.The bacterial eradication rates were 75.0% in trial group and 42.9% in control group.The differences in both clinical cure rates and the bacterial eradication rates between the two groups were statistically significant(P<0.05),but no significant difference in the clinical efficacy rates.No side effects occured in trial group.CONCLUSION Inhaled ambroxol could help to clear P.aeruginosa and might be an ideal adjunctive therapy for the lower respiratory tract infection induced by P.aeruginosa.